Ashita Tolwani, MD, MSc, will receive the Robert G. Narins Award for her many efforts in education and training of the next generation of nephrologists. Dr. Tolwani is professor of medicine at the University of Alabama at Birmingham (UAB).
Dr. Tolwani directed the UAB nephrology fellowship program from 2002 to 2010 and continues as associate program director. In that capacity, she co-directed workshops on curriculum development and assisted in developing the curriculum and teaching tools portion of the ASN website. She wrote the nephrology fellowship manual now available on the website.
A researcher who has devoted her career to investigating RNA will give a state-of-the-art lecture, “RNA Biology and Medicine: A Journey of Unexpected Discovery,” on Sunday, Oct. 25. The speaker, Joan A. Steitz, PhD, is Sterling Professor of Molecular Biophysics and Biochemistry at Yale University and an investigator at the Howard Hughes Medical Institute.
Perhaps her biggest breakthrough came in 1979, when Dr. Steitz and her colleagues described a group of cellular particles called small nuclear ribonucleoproteins (snRNPs), a breakthrough in understanding how RNA is spliced. Subsequently, her laboratory defined the structures and functions of other
“Global Efforts to Curate the Genome” is the title of a state-of-the-art lecture scheduled for Sat., Oct. 24. The speaker will be Heidi Rehm, PhD, a human geneticist and genomic medicine researcher. She is medical director of the Clinical Research Sequencing Platform and an institute member at the Broad Institute in Cambridge, Mass.
She is also chief genomics officer in the department of medicine at Massachusetts General Hospital and a professor of pathology at Mass General, Brigham and Women’s Hospital, and Harvard Medical School. A leader in defining standards for the interpretation of sequence variants, Rehm is
People with kidney diseases should be included in COVID-19 clinical trials—especially vaccine candidates—as a crucial measure that increases “trust in the science and development process for the vaccine among kidney patients,” according to a recent statement of the Kidney Health Initiative (KHI). Including people with kidney diseases and kidney failure, as well as those with undiagnosed reduced kidney function, will ensure the efficacy and safety profiles of any vaccine candidate will be understood in people with kidney diseases, the statement says.
The KHI statement builds on an earlier statement that encouraged inclusion of people with kidney diseases in all COVID-19
The intriguing title of the Robert W. Schrier, MD, Endowed Lectureship is “How the Unknown Unknowns Cause the Increased Peripheral Vascular Resistance.” The speaker, Friedrich (Fred) C. Luft, MD, said he “will report on a single project that spans more than 25 years of clinical and basic research” that demonstrates “how ignorance drives science.”
Internationally recognized for his research in nephrology, hypertension, physiology, and genetics, Dr. Luft is a professor at the Max-Delbrück Center for Molecular Medicine, Charité Medical Faculty, in Berlin, Germany. The lecture is scheduled for Sat., Oct. 24.
ASN will recognize the wide-ranging contributions of Ravi I. Thadhani, MD, MPH, with the presentation of the John P. Peters Award. The Peters Award is given for outstanding contributions to improving the lives of patients and furthering the understanding of the kidneys in health and disease.
Dr. Thadhani is the chief academic officer at Partners Healthcare, dean for academic programs at Harvard Medical School, and a physician at Massachusetts General Hospital. He is the former head of the division of nephrology at Massachusetts General.
Dr. Thadhani has two major areas of research interest: medical complications
The title of the Celeste Castillo Lee Memorial Lectureship will be “Developing Actionable Patient Safety Outcome Metrics for Dialysis.” Scheduled for Sunday, Oct. 25, the speaker will be Allison Tong, PhD, MPH, a principal research fellow and professor at the Sydney School of Public Health, the University of Sydney in Australia.
Dr. Tong has extensive experience in patient-centered outcomes research in chronic disease, particularly CKD. Her work focuses on patient involvement in research, including in the context of research priority setting, the development of core outcomes for research, and in the co-production of clinical trials. She
The president of the National Academy of Medicine will present a state-of-the-art address entitled “Human Genome Editing: Responsible Pathway Forward.” The address is scheduled for Thursday, Oct. 22.
Victor J. Dzau, MD, is also vice chair of the National Research Council. He is chancellor emeritus and James B. Duke Professor of Medicine at Duke University and the former CEO of the Duke University Health System. His previous positions include serving as chair of medicine at Harvard Medical School’s Brigham and Women’s Hospital and chair of the department of medicine at Stanford University.
Nobel Prize winner Sir Peter John Ratcliffe will present the Homer W. Smith Award lecture on Friday, Oct. 23. This award recognizes outstanding contributions to understanding how kidneys function in normal and diseased states. He will speak on “Understanding Cellular Oxygen-Sensing Mechanisms: Implications for Medicine.”
Professor Ratcliffe is director of clinical research at the Francis Crick Institute in London as well as director of the Target Discovery Institute and distinguished scholar of the Ludwig Institute of Cancer Research at Oxford University.
After studying the physiology of renal circulation, Professor Ratcliffe became interested in the regulation of
A researcher with a broad portfolio will provide the “Rationale for Personalized Medicine Approaches to the Management of CKD-Associated Osteoporosis” in the Jack W. Coburn, MD, Endowed Lectureship on Friday, Oct. 23.
The speaker will be Glenn M. Chertow, MD, MPH, who is the Norman S. Coplon Satellite Healthcare Professor of Medicine and chief of the division of nephrology at Stanford University School of Medicine.
In addition to teaching, mentoring, and maintaining an active clinical practice, Dr. Chertow has carried out a robust clinical research program centered on clinical epidemiology, health-services research, decision science,